팩터별 등급: 가치 F, 성장 D, 수익성 D, 모멘텀 C-, 추정치 수정 C+. 매일 갱신되며, 섹터 내 상대 평가라 모든 사용자에게 같은 결과가 표시됩니다.
최근 토론 이슈
[호재] Investors compare VK2735 favorably to Lilly's tirzepatide, citing superior weight loss potential and cheap valuation amid obesity drug discussions. (게시물 5개)
Analysts Seedhouse and pharmdca both cite VK2735 Phase 3 readout as key near-term catalyst, suggesting efficacy may be favorable vs. tirzepatide or retatrutide
첫날 +2.0% · 5일 후 -6.2%
›전개 과정 3회
2026-07-17Law firm probes fiduciaries; Q2 report hinges on VK2735 updates
2026-07-26Q2 call set for July 29; key items include Ph1 maintenance readout and Ph3 oral program initiation
2026-08-03Analysts Seedhouse and pharmdca both cite VK2735 Phase 3 readout as key near-term catalyst, suggesting efficacy may be favorable vs. tirzepatide or retatrutide
Analysts Seedhouse and pharmdca both cite VK2735 Phase 3 readout as key near-term catalyst, suggesting efficacy may be favorable vs. tirzepatide or retatrutide
첫날 +2.0% · 5일 후 -6.2%
›전개 과정 3회
2026-07-17Law firm probes fiduciaries; Q2 report hinges on VK2735 updates
2026-07-26Q2 call set for July 29; key items include Ph1 maintenance readout and Ph3 oral program initiation
2026-08-03Analysts Seedhouse and pharmdca both cite VK2735 Phase 3 readout as key near-term catalyst, suggesting efficacy may be favorable vs. tirzepatide or retatrutide
